Bioventus Profit Margin

The latest profit margin for BVS is 4.94% as of March 2026. That compares with -5.57% in the prior-year period — up 188.8% year over year. That is below the Healthcare sector average of 15.52%. Investors often review this figure alongside Bioventus's historical trend and sector peers before judging valuation or financial health.

Over the past year, BVS's profit margin moved from -5.57% to 4.94% — a 188.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Bioventus's valuation or profitability profile.

Against Healthcare companies, BVS currently prints 4.94% for profit margin, while the sector average sits near 15.52%. That is roughly 68.2% below the sector mean. Large gaps often invite a closer look at Bioventus's growth, margins, and balance sheet.

Profit Margin shows how effectively Bioventus converts resources into returns. At 4.94%, BVS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5.57% in the prior-year period — up 188.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BVS's profit margin (4.94%), review year-over-year change from -5.57%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.